Publication: QSAR-driven rational design of novel dna methyltransferase 1 inhibitors
Issued Date
2020-01-01
Resource Type
ISSN
16112156
Other identifier(s)
2-s2.0-85083213101
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
EXCLI Journal. Vol.19, (2020), 458-475
Suggested Citation
Chuleeporn Phanus-Umporn, Veda Prachayasittikul, Chanin Nantasenamat, Supaluk Prachayasittikul, Virapong Prachayasittikul QSAR-driven rational design of novel dna methyltransferase 1 inhibitors. EXCLI Journal. Vol.19, (2020), 458-475. doi:10.17179/excli2020-1096 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/54441
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
QSAR-driven rational design of novel dna methyltransferase 1 inhibitors
Other Contributor(s)
Abstract
© 2020, Leibniz Research Centre for Working Environment and Human Factors. All rights reserved. DNA methylation, an epigenetic modification, is mediated by DNA methyltransferases (DNMTs), a family of enzymes. Inhibitions of these enzymes are considered a promising strategy for the treatment of several diseases. In this study, a quantitative structure-activity relationship (QSAR) modeling was employed to understand the structure-activity relationship (SAR) of currently available non-nucleoside DNMT1 inhibitors (i.e., indole and oxazoline/1,2-oxazole scaffolds). Two QSAR models were successfully constructed using multiple linear regres-sion (MLR) and provided good predictive performance (R2Tr = 0.850-0.988 and R2CV = 0.672-0.869). Bond infor-mation content index (BIC1) and electronegativity (R6e+) are the most influential descriptors governing the activity of compounds. The constructed QSAR models were further applied for guiding a rational design of novel inhibitors. A novel set of 153 structurally modified compounds were designed in silico according to the important descriptors deduced from the QSAR finding, and their DNMT1 inhibitory activities were predicted. This result demonstrated that 86 newly designed inhibitors were predicted to elicit enhanced DNMT1 inhibitory activity when compared to their parent compounds. Finally, a set of promising compounds as potent DNMT1 inhibitors were highlighted to be further developed. The key SAR findings may also be beneficial for structural optimization to improve properties of the known inhibitors.